Tirofiban After Successful MT Recanalization in AIS
Status:
RECRUITING
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
Acute ischemic stroke with large vessel occlusion is a frequently occurring life-threatening condition. Although endovascular treatment can effectively open occluded vessels, the successful reperfusion rate exceeds 80%, but the rate of good prognosis is less than 50%. The current clinical focus is on how to improve futile recanalization. Tirofiban is widely used in the treatment of stroke, as it can effectively prevent vascular reocclusion and improve microcirculation perfusion. It has the potential to improve futile recanalization, but there is a lack of high-level evidence-based medical support. This multicenter, prospective, double-blind, randomized controlled trial was conducted to assess the effectiveness and safety of sequential tirofiban therapy following successful mechanical thrombectomy within 24 hours of onset.
Phase:
PHASE2
Details
Lead Sponsor:
Xiang Luo
Collaborators:
Affiliated Hospital of Chengde Medical University Beijing Tiantan Hospital Hanyang University Huangshi Central Hospital Jingzhou Central Hospital Nanyang Central Hospital Renmin Hospital of Wuhan University Second Affiliated Hospital of Soochow University Taihe Hospital The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture The Fifth Hospital of Wuhan The First Affiliated Hospital of Yangtze University The First Affiliated Hospital of Zhengzhou University Wuhan Central Hospital Wuhan Hospital of Traditional Chinese Medicine Wuhan Puren Hospital Wuhan Third Hospital Xiangyang No.1 People's Hospital Xianning Central Hospital Yichang Central People's Hospital Zhongnan Hospital